Guest Medical Editor's Page
The Central Vein Sign
Is 1.5 T MRI still relevant for diagnosis of multiple sclerosis?
Evanthia Bernitsas, MD
Point/Counterpoint: Neurofilament Light
Ready for prime time as a biomarker for multiple sclerosis or not?
Adil Javed, MD, PhD; and James Stankiewicz MD, FAAN
Sphingosine-1-Phosphate Modulators for Multiple Sclerosis
Sphingosine-1-phosphate modulators may act through more than just inhibition of neuroimmune and neuroinflammatory effects of multiple sclerosis.
Mark B. Skeen, MD
AntiCD20+ agents are among the highest efficacy treatments for multiple sclerosis.
Brian Barry, MD; and Robert K. Shin, MD
Cladribine is an effective oral treatment for multiple sclerosis with potential for long-term remission.
Crystal Dixon, MD; Miguel Melo-Bicchi, MD; and Kottil W. Rammohan, MD
Drugs in Development for Multiple Sclerosis
Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.
Konstantin Balashov, MD, PhD
Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes
Are the changes a step forward or a step back?
Svetlana Primma Eckert, MD; Bianca Weinstock-Guttman, MD; and Stephen Krieger, MD
Headache Horizons: Headaches That Roam the Night
Many headache types can occur in the night, including some that may be exclusive to dream periods.
Peter McAllister, MD
Neuromuscular Notes: Taking the Mis- out of CIDP Diagnosis
Criteria exist for CIDP and should be used for diagnosis and management.
Karissa Gable, MD
About The Cover Artist